Abstract 19071: Impact of Angiotensin Receptor Blocker on Development of Glucose Intolerance and New-onset Diabetes Mellitus in Asian Population
Background; Angiotensin receptor blocker (ARB) is being extensively used to control hypertension. But, there have been limited data whether ARB is associated with increased incidence of new-onset diabetes mellitus (DM) or impaired glucose intolerance (IGT).
Methods; We investigated total 13,561 patients (pts) that was glycerate hemoglobin level < 6.0% and fasting glucose level < 124 mg/dL (ARB therapy group=3421 and control group=9808) from January 2004 to February 2012. To adjust potential confounders, a propensity score matched analysis was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired fasting glucose (IFG). Also, multivariable cox-regression analysis by adjusted by aforementioned variables was performed to determine the impact of statin therapy on the incidence of new-onset DM, IGT, and IFG.
Results; Mean follow-up duration was 534±604 days in all-pt group, and 608±607 days in propensity score matching group. After propensity score match, total 5632 pts (ARB group=2816 and control group = 2816) were enrolled for analysis. Baseline characteristics was similar between the two groups except the more use of diuretics (38% vs. 35.5%, p=0.047). In Kaplan-Meyer curve, there was no difference between the two groups (p=0.428, figure A). Also, in cox-regression analysis performed in all pts, ARB therapy was not associated with the increased incidence of primary end-point (figure B).
Conclusions; In the present study, there was no clear association between ARB therapy and IGT or new-onset DM in a series of cardiovascular pts in Asian population.
- © 2012 by American Heart Association, Inc.